Marseille, France, March 25, 2025 4:30 p.m. EST/21:30 CET– ImCheck Therapeuticsannounced today it will present updated results from its ongoing open-label, randomized Phase I/II study EVICTION at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois, USA. The poster presentation will provide efficacy, safety, pharmacodynamics and dose selection data on the novel γ9δ2 T-cell activator, ICT01, in combination with azacitidine and venetoclax for the treatment of patients with newly diagnosed AML.
Details of the poster presentation at AACR 2025 are:
Session: Phase 0 and Phase I Clinical Trials
Abstract number: CT024
Presenter: Abhishek Maiti, University of Texas MD Anderson Cancer Center
Authors:Abhishek Maiti, Pierre Peterlin, Daniel Morillo, Jose-Miguel Torregrosa-Diaz, Matthew Ulrickson, Agustin Penedo, Aude De Gassart, Elisabeth Wieduwild, Emmanuel Valentin, Maelle Mairesse, Patrick Brune, Katrien Lemmens, Stephan Braun, Daniel Olive, Naval G. Daver, Sylvain Garciaz, Pierre-Yves Dumas
Date: Monday, April 28, 2025
Time: 9:00 am- 12:00 pm EST
Location: Poster Section 49 / Poster Board Number: 3
The AACR poster presentation will provide an update on the data in AML patients most recently presented at the American Society of Hematology (ASH) Annual Meeting 2024 showing that ICT01 administered in combination with azacitidine and venetoclax demonstrated promising efficacy without compromising safety.
The AACR poster will be available on ImCheck’s corporate website after the poster sessions have been opened.